Rectal cancer
Conditions
Interventions
1:Preoperative IMRT (GTV 50.6Gy/22 fractions, CTV 41.8 Gy/22 frations, the boost to the primary tumor would be administered synchronously with the whole pelvis) with concurrent capecitabine 825 mg/m2
Sponsors
Beijing Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: All patients were histologically confirmed as the rectal adenocarcinoma within 10 cm from the anal verge, with no evidence of distant metastases. The T/N situation was stage T3 to T4 with any N, or any T with N1 to N2. Patients presenting with T2N0 tumors located within 5 cm from the anal verge could also be included.The age for this trial defined as between 18-75 years old. Patients were also required to have a WHO performance status of 0 or 1 with adequate liver, kidney, and bone marrow function.
Exclusion criteria
Exclusion criteria: Patients who had prior history of chemotherapy or pelvic radiation therapy were excluded. Patients with a history of other malignancy were also excluded. Other exclusion criteria included the acute obstructive symptoms,unresectable disease, sensitivity to fluoropyrimidines, and any serious conditions not suitable for chemoradiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toxicity during chemoradiation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Local recurrence, Distant metastases,Overall survival; | — |
Countries
China
Contacts
Public ContactYong Cai
Outcome results
None listed